ATE445646T1 - Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren - Google Patents

Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren

Info

Publication number
ATE445646T1
ATE445646T1 AT02784853T AT02784853T ATE445646T1 AT E445646 T1 ATE445646 T1 AT E445646T1 AT 02784853 T AT02784853 T AT 02784853T AT 02784853 T AT02784853 T AT 02784853T AT E445646 T1 ATE445646 T1 AT E445646T1
Authority
AT
Austria
Prior art keywords
express
tumor cells
erbb2 receptor
human mini
erbb2
Prior art date
Application number
AT02784853T
Other languages
English (en)
Inventor
Alessio Giuseppe D
Renata Piccoli
Lorenzo Claudia De
Donald Balfour Palmer
Mary Alice Ritter
Original Assignee
Biotecnol Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecnol Sa filed Critical Biotecnol Sa
Application granted granted Critical
Publication of ATE445646T1 publication Critical patent/ATE445646T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02784853T 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren ATE445646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
PCT/EP2002/007671 WO2003006509A2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor

Publications (1)

Publication Number Publication Date
ATE445646T1 true ATE445646T1 (de) 2009-10-15

Family

ID=11455653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784853T ATE445646T1 (de) 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren

Country Status (13)

Country Link
US (2) US7585952B2 (de)
EP (1) EP1432737B1 (de)
AT (1) ATE445646T1 (de)
CA (1) CA2453435A1 (de)
DE (1) DE60234041D1 (de)
DK (1) DK1432737T3 (de)
ES (1) ES2334895T3 (de)
IT (1) ITRM20010408A1 (de)
NZ (1) NZ531035A (de)
PT (1) PT1432737E (de)
SI (1) SI1432737T1 (de)
WO (1) WO2003006509A2 (de)
ZA (1) ZA200401044B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (it) * 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
EP2010221B1 (de) * 2006-04-21 2012-02-29 mAB-Factory GmbH Antikörper-rnase-konjugat
KR20090058512A (ko) * 2006-08-04 2009-06-09 아스트라제네카 아베 Ｅｒｂｂ2에 대한 인간 항체
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
CA2793753C (en) 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
WO2014200891A1 (en) * 2013-06-11 2014-12-18 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES Her2-specific monoclonal antibodies and conjugates thereof
EP3038645B1 (de) * 2013-08-26 2019-01-30 Health Research, Inc. Verfahren zur behandlung von erbb2-positiven karzinomen
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN107075490A (zh) 2014-08-20 2017-08-18 健康研究公司 用于预防和/或治疗erbb1阳性癌症的方法
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309780A (ja) 1994-03-02 1995-11-28 N Bii T Kk 抗癌剤
US5795961A (en) 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
GB9805660D0 (en) 1998-03-18 1998-05-13 Unichema Chemie Bv Improvements in and relating to fatty acid metabolism
US6135941A (en) * 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2001014558A1 (en) 1999-08-26 2001-03-01 Morphosys Ag Human antibodies or fragments thereof binding to hla-cw6
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use

Also Published As

Publication number Publication date
WO2003006509A2 (en) 2003-01-23
US7585952B2 (en) 2009-09-08
ITRM20010408A0 (it) 2001-07-10
NZ531035A (en) 2005-04-29
ITRM20010408A1 (it) 2003-01-10
CA2453435A1 (en) 2003-01-23
DK1432737T3 (da) 2010-02-08
EP1432737B1 (de) 2009-10-14
US20070258985A1 (en) 2007-11-08
WO2003006509A3 (en) 2003-11-20
PT1432737E (pt) 2010-02-17
US8227585B2 (en) 2012-07-24
ZA200401044B (en) 2004-10-22
US20100173978A1 (en) 2010-07-08
DE60234041D1 (de) 2009-11-26
SI1432737T1 (sl) 2010-02-26
ES2334895T3 (es) 2010-03-17
EP1432737A2 (de) 2004-06-30

Similar Documents

Publication Publication Date Title
DE60234041D1 (de) Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren
MY154009A (en) Anti-alpha v beta 6 antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
BE2016C015I2 (de)
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
WO2004001381A8 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2004029092A3 (fr) Anticorps pour adcc et induisant la production de cytokines.
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
WO2005012493A3 (en) Anti-cd19 antibodies
GEP20074222B (en) Antibodies to cd40
AU2003215188A8 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
EP1187591A4 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
TW200617023A (en) Antibodies directed against amyloid-beta peptide and methods using same
PE20070374A1 (es) ANTICUERPOS ANTI-MAdCAM
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
MX2007000103A (es) Bibliotecas de anticuerpos universales.
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1432737

Country of ref document: EP